Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource rightarrow Recombinant Protein rightarrow HLA-DRA  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Menu separator
separator
ELISA Kit ELISA Kit
CLIA Kit CLIA Kit
PCR Kit PCR Kit
Monoclonal Antibody Monoclonal Antibody
Polyclonal Antibody Polyclonal Antibody
Secondary Antibody Secondary Antibody
Antigen Antigen
Biochemical Biochemical
cDNA Clone cDNA Clone
siRNA siRNA
Peptide Peptide
Recombinant/Purified Protein Rec./Purified Protein

Custom ELISA Kit Custom ELISA Kit
Custom Protein Custom Protein
Custom Antibody Custom Antibody
Antibody Matched Pairs Antibody Matched Pairs
Antibody & Corresponding Blocking Peptide Pairs Antibody Peptide Pairs
Phospho-Specific Antibodies Phospho Antibodies
Products by Disease Products by Disease
Products by Pathway Products by Pathway
Products by Tissue Products by Tissue

arrow Advanced Search
arrow Submit Technical Q&A
arrow International Distributors
arrow Contact Us
separator
Our Best Sellers moreseparator
separator
 • MAP1LC3B Antibody
 • R-Spondin 1 (RSPO1) ELISA Kit
 • VPS35 Antibody
 • EED ELISA Kit
 • 40S ribosomal protein S30 (FAU) ELISA Kit
 • FTL Recombinant Protein
 • adrenergic, beta-1-, receptor (ADRB1) ELISA Kit
 • Fbn ELISA Kit
 • Multidrug resistance protein 1 (Abcb1) Recombinant Protein
 • Hepatitis C Virus Nucleocapsid (HCV) Recombinant Protein
 • CD57 Antibody
 • USP12 Antibody
 • KLF4 Antibody
 • streptolysin O (SLO) ELISA Kit
 downarrow more ...
separator
separator
DatasheetFull DatasheetPrinter Friendly DatasheetPrint This DatasheetAdd to Compare ListHave Questions? Ask UsRequest for a Quotation today

HLA-DRA recombinant protein :: HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) Recombinant Protein

Scan QR to view Datasheet Catalog #    MBS1093239
SDS-Page
Unit / Price
0.01 mg (Yeast)  /  $170 +1 FREE 8GB USB
0.01 mg (E-Coli)  /  $195 +1 FREE 8GB USB
0.05 mg (Yeast)  /  $220 +1 FREE 8GB USB
0.05 mg (E-Coli)  /  $255 +1 FREE 8GB USB
0.1 mg (Yeast)  /  $345 +1 FREE 8GB USB
0.1 mg (E-Coli)  /  $420 +1 FREE 8GB USB
0.2 mg (Yeast)  /  $545 +1 FREE 8GB USB
0.2 mg (E-Coli)  /  $665 +1 FREE 8GB USB
0.5 mg (Yeast)  /  $900 +1 FREE 8GB USB
0.05 mg (Baculovirus)  /  $920 +1 FREE 8GB USB
0.5 mg (E-Coli)  /  $1,090 +1 FREE 8GB USB
0.05 mg (Mammalian-Cell)  /  $1,160 +1 FREE 8GB USB
0.1 mg (Baculovirus)  /  $1,160 +1 FREE 8GB USB
1 mg (Yeast)  /  $1,410 +1 FREE 8GB USB
0.5 mg (Baculovirus)  /  $1,675 +2 FREE 8GB USB
1 mg (E-Coli)  /  $1,725 +2 FREE 8GB USB
0.1 mg (Mammalian-Cell)  /  $1,765 +2 FREE 8GB USB
1 mg (Baculovirus)  /  $2,235 +2 FREE 8GB USB
 
 Go to:   rightarrow  Product Names   rightarrow Product Info   rightarrow Accession #s   rightarrow Product Desc   rightarrow Diseases/Tissues/Pathways   rightarrow Applications   rightarrow References 
 Product Name   

HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA), Recombinant Protein

★Popular Item★
 Also Known As   

Recombinant Human HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA), partial

 Product Gene Name   

HLA-DRA recombinant protein

[Similar Products]
 Research Use Only    For Research Use Only. Not for use in diagnostic procedures.
Table BarTOPTable Bar
 MBS1093239 COA    COA PDF
 Sequence Positions    26-254. Full length of mature protein
 Sequence    IKEEHVIIQA EFYLNPDQSG EFMFDFDGDE IFHVDMAKKE TVWRLEEFGR FASFEAQGAL ANIAVDKANL EIMTKRSNYT PITNVPPEVT VLTNSPVELR EPNVLICFID KFTPPVVNVT WLRNGKPVTT GVSETVFLPR EDHLFRKFHY LPFLPSTEDV YDCRVEHWGL DEPLLKHWEF DAPSPLPETT ENVVCALGLT VGLVGIIIGT IFIIKGVRKS NAAERRGPL
 OMIM    142860
 3D Structure    ModBase 3D Structure for P01903
Section Bar
 Host    E Coli or Yeast or Baculovirus or Mammalian Cell
Section Bar
 Purity/Purification    Greater than 85% as determined by SDS-PAGE. (lot specific)
 Form/Format    Liquid containing glycerol
 Tag Information    This protein contains an N-terminal tag and may also contain a C-terminal tag. Tag types are determined by various factors including tag-protein stability, please inquire for tag information.
 Sterility    Sterile filter available upon request.
 Endotoxin    Low endotoxin available upon request.
Section Bar
 Species    Homo sapiens (Human)
 Storage Buffer    Tris-based buffer, 50% glycerol
 Tag Information    Tag type will be determined during the manufacturing process
Section Bar
 Preparation and Storage    Store at -20 degrees C. For long-term storage, store at -20 degrees C or -80 degrees C. Store working aliquots at 4 degrees C for up to one week. Repeated freezing and thawing is not recommended.
 ISO Certification    Manufactured in an ISO 9001:2008 Certified Laboratory.
 Other Notes    Small volumes of HLA-DRA recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Table BarTOPTable Bar
 

Related Product Information for HLA-DRA recombinant protein

   Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal
lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal
lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
 Product Categories/Family for HLA-DRA recombinant protein    Immunology
Section Bar
 SDS-Page of HLA-DRA recombinant protein    HLA-DRA recombinant protein SDS-Page image
(Note: Representative image, actual molecular weight may vary depending on Tag type and expression host)
Table BarTOPTable Bar
NCBI/Uniprot data below describe general gene information for HLA-DRA. It may not necessarily be applicable to this product.
 NCBI GI #    52426774
 NCBI GeneID    3122
 NCBI Accession #    NP_061984.2 [Other Products]
 NCBI GenBank Nucleotide #    NM_019111.4 [Other Products]
Section Bar
 UniProt Primary Accession #    P01903 [Other Products]
 UniProt Secondary Accession #    Q30160; Q6IAZ1; Q861I2; Q9TP70; A2BET4 [Other Products]
 UniProt Related Accession #    P01903 [Other Products]
 Molecular Weight    30.0 kDa
Table BarTOPTable Bar
 NCBI Official Full Name    HLA class II histocompatibility antigen, DR alpha chain
 NCBI Official Synonym Full Names    major histocompatibility complex, class II, DR alpha
 NCBI Official Symbol    HLA-DRA [Similar Products]
 NCBI Official Synonym Symbols   
HLA-DRA1
[Similar Products]
 NCBI Protein Information    HLA class II histocompatibility antigen, DR alpha chain
 UniProt Protein Name    HLA class II histocompatibility antigen, DR alpha chain
 UniProt Synonym Protein Names   
MHC class II antigen DRA
 Protein Family    HLA class II histocompatibility antigen
 UniProt Gene Name    HLA-DRA [Similar Products]
 UniProt Synonym Gene Names    HLA-DRA1 [Similar Products]
Section Bar
 NCBI Summary for HLA-DRA    HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq, Jul 2008]
Section Bar
 UniProt Comments for HLA-DRA    Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Table BarTOPTable Bar
 

Product References and Citations for HLA-DRA recombinant protein

   "Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain." Schamboeck A., Korman A.J., Kamb A., Strominger J.L. Nucleic Acids Res. 11:8663-8675(1983)
Section Bar
 Research Articles on HLA-DRA    1. This study demonstrated that only the non-suicidal depressed subgroup revealed significantly lower microglial reaction, i.e., a decreased density of HLA-DR positive microglia versus both depressed suicide victims and controls.
Table BarTOPTable Bar
 Precautions    All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
 Disclaimer    While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Table BarTOPTable Bar
Products associated with HLA-DRA recombinant proteinPathways associated with HLA-DRA recombinant protein
 Reference Product  PubMed Publications
 HLA-DR4 recombinant protein  >103 publications with HLA-DRA and HLA-DR4
 CD4 recombinant protein  >62 publications with HLA-DRA and CD4
 HLA-DRB5 recombinant protein  >44 publications with HLA-DRA and HLA-DRB5
 CD74 recombinant protein  >6 publications with HLA-DRA and CD74
 HLA-DR15 recombinant protein  >2 publications with HLA-DRA and HLA-DR15
 Products by Pathway  Pathway Diagram
 Adaptive Immune System Pathway antibodies  Adaptive Immune System Pathway Diagram
 Allograft Rejection Pathway antibodies  Allograft Rejection Pathway Diagram
 Allograft Rejection Pathway antibodies  Allograft Rejection Pathway Diagram
 Allograft Rejection Pathway antibodies  Allograft Rejection Pathway Diagram
 Antigen Processing And Presentation Pathway antibodies  Antigen Processing And Presentation Pathway Diagram
 Antigen Processing And Presentation Pathway antibodies  Antigen Processing And Presentation Pathway Diagram
 Asthma Pathway antibodies  Asthma Pathway Diagram
 Asthma Pathway antibodies  Asthma Pathway Diagram
 Autoimmune Thyroid Disease Pathway antibodies  Autoimmune Thyroid Disease Pathway Diagram
 Autoimmune Thyroid Disease Pathway antibodies  Autoimmune Thyroid Disease Pathway Diagram
Diseases associated with HLA-DRA recombinant proteinOrgans/Tissues associated with HLA-DRA recombinant protein
 Disease Name  Pubmed Publications
 Nervous System Diseases Antibodies  >75 publications with HLA-DRA and Nervous System Diseases
 Skin Diseases Antibodies  >47 publications with HLA-DRA and Skin Diseases
 Multiple Sclerosis Antibodies  >44 publications with HLA-DRA and Multiple Sclerosis
 Necrosis Antibodies  >34 publications with HLA-DRA and Necrosis
 Inflammation Antibodies  >33 publications with HLA-DRA and Inflammation
 Lung Diseases Antibodies  >24 publications with HLA-DRA and Lung Diseases
 Liver Diseases Antibodies  >23 publications with HLA-DRA and Liver Diseases
 Kidney Diseases Antibodies  >18 publications with HLA-DRA and Kidney Diseases
 Disease Models, Animal Antibodies  >16 publications with HLA-DRA and Disease Models, Animal
 Neoplasms, Experimental Antibodies  >15 publications with HLA-DRA and Neoplasms, Experimental
 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >292 publications with HLA-DRA and Blood
 Skin Antibodies  >26 publications with HLA-DRA and Skin
 Bone Antibodies  >23 publications with HLA-DRA and Bone
 Bone Marrow Antibodies  >19 publications with HLA-DRA and Bone Marrow
 Liver Antibodies  >18 publications with HLA-DRA and Liver
 Kidney Antibodies  >17 publications with HLA-DRA and Kidney
 Thyroid Antibodies  >14 publications with HLA-DRA and Thyroid
 Pancreas Antibodies  >14 publications with HLA-DRA and Pancreas
 Muscle Antibodies  >12 publications with HLA-DRA and Muscle
 Thymus Antibodies  >12 publications with HLA-DRA and Thymus
Table BarTOPTable Bar
horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions